| Overview |
| bs-5032R-Biotin |
| Agpat2 Polyclonal Antibody, Biotin Conjugated |
| ELISA, IHC-P, IHC-F |
| Human, Mouse, Rat, Dog, Cow, Pig, Horse |
| Specifications |
| Biotin |
| Rabbit |
| KLH conjugated synthetic peptide derived from human Agpat2 |
| 121-220/278 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| Store at -20°C for 12 months. |
| Target |
| 10555 |
| Cell membrane |
| LPAAB; BSCL; BSCL1; EC 2.3.1.51; LPAAB; LPAAT beta; Lysophosphatidic acid acyltransferase beta; 1 acyl sn glycerol 3 phosphate acyltransferase beta; 1 acylglycerol 3 phosphate O acyltransferase 2; 1 AGP acyltransferase 2; 1 AGPAT2 antibody Berardinelli Seip congenital lipodystrophy.PLCB_HUMAN |
| Agpat2 is a member of the 1-acylglycerol-3-phosphate O-acyltransferase family. It is located within the endoplasmic reticulum membrane and converts lysophosphatidic acid to phosphatidic acid, the second step in de novo phospholipid biosynthesis. Mutations in its have been associated with congenital generalized lipodystrophy (CGL), or Berardinelli-Seip syndrome, a disease characterized by a near absence of adipose tissue and severe insulin resistance. Alternate transcriptional splice variants, encoding different isoforms, have been characterized. |
| Application Dilution |
| ELISA |
1:500-1000 |
| IHC-P |
1:200-400 |
| IHC-F |
1:100-500 |
Powered by Bioz